STAT

Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs

Retrieved on: 
Monday, April 8, 2024
Engagement, STAT, Postural orthostatic tachycardia syndrome, The Washington Post, POTS, Patient, Public, COVID-19, Research, Black, Volunteering, NIH, News, Business News, ScienceDirect, PTLDS, M.E, Management

Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.

Key Points: 
  • Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.
  • Solve Board Chair John Nicols states, "We congratulate Emily and look forward to her leadership."
  • Solve also announces the publication of their newest white paper, co-authored by Emily, " A Home for Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH ."
  • BIPOC (Black, Indigenous, and other People of Color), Latino/Latina, LGBTQIA+, and marginalized, underserved and economically disadvantaged populations are disproportionately impacted by IACCIs.

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Automatic Data Processing, Inc., and American Century Investments Services, Inc.

Retrieved on: 
Tuesday, February 27, 2024
Class Action Lawsuit, Professional Services, Legal, Court, ACI, PSLRA, Complaint, District court, ADP, STAT

Federman & Sherwood announces that on January 16, 2024, a class action lawsuit was filed in the United States District Court for the Middle District of Florida against Automatic Data Processing, Inc. (ADP), and American Century Investments Services, Inc. (ACI) (collectively, Defendants).

Key Points: 
  • Federman & Sherwood announces that on January 16, 2024, a class action lawsuit was filed in the United States District Court for the Middle District of Florida against Automatic Data Processing, Inc. (ADP), and American Century Investments Services, Inc. (ACI) (collectively, Defendants).
  • The Complaint alleges violations of federal securities laws, including Section 11, 12(a)(2), 15(a), 15(c), and 20(a) of the Securities Exchange Act of 1934, N.J.S.A.
  • 49:3-52 and 49:3-56, Florida Deceptive and unfair Trade Practices Act (FDUTPA), Fla. Stat.
  • You may move the Court no later than Monday, April 29, 2024, to serve as a lead plaintiff for the entire Class.

Eagle Telemedicine Launches New Rural Care Alliance to Extend Telemedicine Specialty Services to Community Hospitals in Need

Retrieved on: 
Tuesday, February 13, 2024
STAT, National Rural Health Association, NRHA, Hospital, Physician, Patient, Travel, Nursing

ATLANTA, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Eagle Telemedicine, the leader in technology-enabled inpatient and outpatient care for sustainable healthcare resilience, announces the creation of the Eagle Rural Care Alliance. The Eagle Rural Care Alliance is a new program that opens access to telemedicine specialty services by fostering alliances between rural facilities to maximize economies of scale and support access to critically important specialties for their communities. The new program bundles multiple hospitals' needs together to deliver affordable access to telemedicine specialty physicians in economically consumable increments. This enables rural and community hospitals to offer specialty clinics to patients in their community that would otherwise forgo treatment or have to travel hours to get the specialized care they require.

Key Points: 
  • The Eagle Rural Care Alliance is a new program that opens access to telemedicine specialty services by fostering alliances between rural facilities to maximize economies of scale and support access to critically important specialties for their communities.
  • Our new Eagle Rural Care Alliance is solving this problem by bundling hospitals with similar needs together to cost-effectively meet the minimum volume requirements to reserve telemedicine specialists.
  • The Eagle Rural Care Alliance is offered to hospitals of every size and location across 17 physician specialties.
  • The Eagle Rural Care Alliance is available now to any hospitals needing increased access to board certified specialty physicians to serve patients in their community.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Ventyx Biosciences, Inc. (VTYX)

Retrieved on: 
Thursday, January 4, 2024
Psoriasis, STAT, News, Private investigator

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX ).

Key Points: 
  • NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX ).
  • The investigation concerns whether Ventyx and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com .

USPack Launches USPack Healthcare and Unveils New Branding

Retrieved on: 
Thursday, January 4, 2024
Pharmacy, Ageing, Name, Health, STAT, Nuclear medicine

ORLANDO, Fla., Jan. 4, 2024 /PRNewswire/ -- USPack, a national leader in same-day, final-mile delivery solutions, and a NewSpring Holdings platform company, today unveils new branding and launches USPack Healthcare. These moves mark a significant milestone in USPack's evolution and position the company at the forefront of innovation and customized final mile solutions, catering to the growing needs of healthcare, retail, and big & bulky customers in the modern logistics landscape.

Key Points: 
  • ORLANDO, Fla., Jan. 4, 2024 /PRNewswire/ -- USPack, a national leader in same-day, final-mile delivery solutions, and a NewSpring Holdings platform company, today unveils new branding and launches USPack Healthcare .
  • In response to the ever-evolving landscape of the healthcare industry, USPack is committed to enhancing operational efficiency and ensuring the timely delivery of critical supplies by formalizing USPack Healthcare.
  • We will build on our already robust service-centric solutions for routed and STAT final-mile solutions with the launch of USPack Healthcare," says Mike Clark, USPack CEO.
  • Our new USPack branding and the rollout of USPack Healthcare underscore the deliberate evolution of USPack as we look to expand our trusted customer relationships across all market sectors."

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

Retrieved on: 
Tuesday, November 21, 2023
Quality of life, Lung cancer, PVD, Survival, NF-κB, BRAF, Research, Bromodeoxyuridine, Melanoma, SH-4, Incidence, Factorization of polynomials, Cancer, COX2, MTT, Neoplasm, STAT, ATP, Enzyme, Manuscript, Cell, Patient, Agonal respiration, Canadian International Council, Vaccine

BERWYN, PA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed International Journal of Molecular Sciences in a manuscript titled, “In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.”1 The publication by Gambichler, et al. (2023) details the anti-tumor activity of the GAPDH inhibitor misetionamide (GP-2250) in BRAF-mutated melanoma cell lines and benign melanocytes. Mutated BRAF is a potent oncogene involved in sending signals inside cells which are involved in directing cell growth and is overexpressed in melanomas, non-small cell lung cancer, and other tumor types.

Key Points: 
  • (2023) details the anti-tumor activity of the GAPDH inhibitor misetionamide (GP-2250) in BRAF-mutated melanoma cell lines and benign melanocytes.
  • Results of this preclinical study showed misetionamide has anti-neoplastic effects in BRAF-mutated melanoma cell lines regarding tumor cell viability, proliferation, and apoptosis/necrosis.
  • The team studied three melanoma cell lines and one primary melanocyte cell line (Ma-Mel-61a, Ma-Mel-86a, SH-4, and ATCC-PCS-200-013, respectively) which were exposed to different misetionamide doses.
  • “We are very excited to see the cancer cell killing benefits of misetionamide demonstrated in this study.

Media Advisory: Surescripts Sponsors STAT in DC Event, Convening Healthcare Industry Stakeholders on Policies to Ease Medicine’s Pain

Retrieved on: 
Tuesday, November 21, 2023
Managed Care, General Health, Pharmaceutical, Health, Patient, Environment, STAT, Surescripts

In addition, Laura Bray, chief change maker and founder, Angels for Change will share her story, Hunting Down my Daughter’s Chemotherapy.

Key Points: 
  • In addition, Laura Bray, chief change maker and founder, Angels for Change will share her story, Hunting Down my Daughter’s Chemotherapy.
  • “With challenges like health care provider burnout, drug shortages and the rising cost of care making headlines each day, it's become even more critical to have open and informed conversations with healthcare experts and stakeholders.
  • These conversations become the foundation for actions we can take to help healthcare heal itself and provide better informed, safe and less costly care for patients across the nation,” said Frank Harvey, Chief Executive Officer of Surescripts.
  • “We welcome the opportunity to convene these healthcare industry experts and stakeholders to share information and work collaboratively to improve the environment for our patients who have entrusted us with their care,” added Harvey.

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Ventyx Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 11, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Jeanne Eagels (film), Psoriasis, Telephone, News, STAT

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) on behalf of Ventyx stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) on behalf of Ventyx stockholders.
  • Our investigation concerns whether Ventyx has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • On November 6, 2023, STAT published an article regarding Ventyx’s decision to halt the development of an experimental drug for treating plaque psoriasis.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Ventyx Biosciences, Inc. (VTYX)

Retrieved on: 
Thursday, November 9, 2023
Class Action Lawsuit, Professional Services, Legal, Psoriasis, News, STAT, Private investigator

The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX ).

Key Points: 
  • The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX ).
  • The investigation concerns whether Ventyx and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com .

STAT to host fifth annual flagship STAT Summit

Retrieved on: 
Tuesday, October 10, 2023
Parkinson's disease, Eli Lilly and Company, Health, Michael J. Lenardo, State room, Interest, St. Jude Children's Research Hospital, GSK, The Michael J. Fox Foundation, Death, Summit, University of Washington, STAT, University, Medicine, Hospital, Dana–Farber Cancer Institute, Disease, Eli Lilly, Emergency medicine, James R. Downing, Biogen, Science, Priscilla, Violence, University of Chicago Medical Center, Patient, HMS, University of Chicago, Pharmaceutical industry, Management, Nursing

BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit, later this month. The hybrid event will take place on October 18-19, 2023, at the State Room in Boston, with programming beginning at 9:00 a.m. ET each day. The Summit will feature frank conversations on vital topics with C-suite industry leaders, and spirited discussions with leading academics and patient advocates on the biggest challenges across health care today.

Key Points: 
  • 2023 STAT Summit will feature leading executives from Eli Lilly, Biogen, GSK, and more, with virtual appearances from Michael J.
  • Fox, Mark Zuckerberg and Priscilla Chan
    BOSTON, Oct. 10, 2023 /PRNewswire/ -- STAT , the leading media company reporting on health, science, and medicine, is set to host its fifth annual flagship event, the 2023 STAT Summit , later this month.
  • The 2023 STAT Summit is presented by St. Jude Children's Research Hospital, and will feature a discussion with James R. Downing, M.D., St. Jude Children's Research Hospital president and CEO.
  • Top executives, key scientists, economists and health outcomes researchers will take the Summit stage to explore solutions together.